Aristea Therapeutics emerged Dec. 18 with a $15 million series A round and mission revolving around inflammatory diseases.
The San Diego company obtained the rights to its lead program, RIST4721, from major pharmaceutical AstraZeneca. Plans call for starting a phase 2 clinical trial in early 2019.
Aristea didn’t state which inflammatory disease indications it’s targeting, instead touting its leadership in a news release. James Mackay, company founder and CEO, was formerly the CEO of Ardea Biosciences, which AstraZeneca acquired in 2012.
Prior to this, he held executive positions at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas.
Beyond RIST4721, Aristea wants to build a drug pipeline.
“The Aristea team has deep experience in the development and commercialization of novel medicines, highlighted by eight previous drug product approvals in a broad range of therapeutic categories including neuroscience, diabetes/metabolic diseases, inflammation, oncology and infectious diseases,” said the news release.
Novo Holdings provided the $15 million in funding.